Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Garth Powis's publication output changed over time?
ScholarIQpublication output · 1976–2015
Output grew0% over the shown period — from 1 works in 1976 to 1 in 2015.
1
1
1
1
2
1
1
2
1
1
1976198819891994200020012003201220132015
What are the most-cited papers on Garth Powis?
ScholarIQmost cited works
Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer
Scott Kopetz, Jayesh Desai, Emily Chan, J. Randolph Hecht, Peter J. O’Dwyer, Dipen M. Maru, Van K. Morris, Filip Jankú, Arvind Dasari, Woonbok Chung, Jean‐Pierre J. Issa, Peter Gibbs, Brian P. James, Garth Powis, K. B. Nolop, Suman Bhattacharya, Leonard B. Saltz
Journal of Clinical Oncology. 2015697 CitationsOPEN ACCESS
Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
Garth Powis, Rosanne Bonjouklian, Margareta Berggren, Alfred Gallegos, Robert T. Abraham, Curtis L. Ashendel, Leon H. Zalkow, William F. Matter, Jeffrey A. Dodge, Gerald B. Grindey
PubMed. 1994692 Citations
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle, Lauren A. Byers, Edward S. Kim, Pierre Saintigny, J. Jack Lee, George R. Blumenschein, Anne S. Tsao, Suyu Liu, Jill E. Larsen, Jing Wang, Lixia Diao, Kevin R. Coombes, Lu Chen, Shuxing Zhang, Mena Abdelmelek, Ximing Tang, Vassiliki A. Papadimitrakopoulou, John D. Minna, Scott M. Lippman, Waun Ki Hong, Roy S. Herbst, Ignacio I. Wistuba, John V. Heymach, Garth Powis
JNCI Journal of the National Cancer Institute. 2012532 CitationsOPEN ACCESS
Related on ScholarIQ
The University of Texas MD Anderson Cancer Center
Institution
Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer
Paper
Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
Paper
Passing the baton: the HIF switch
Paper
Thioredoxin reductase
Paper
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Paper